Cargando…
Effects of Pentoxifylline on Oxygenation and Exercise Tolerance in Patients with Severe Chronic Obstructive Pulmonary Disease
Background: It was hypothesized that the use of Pentoxifylline would increase arterial O2 saturation and increase exercise tolerance in patients with Chronic Obstructive Pulmonary Disease (COPD). Methods: We tested this hypothesis in 23 patients with COPD and pulmonary hypertension. Patients were ra...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Shiraz University of Medical Sciences
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3771218/ https://www.ncbi.nlm.nih.gov/pubmed/24031106 |
_version_ | 1782284172198412288 |
---|---|
author | Fallahi, Mohammad Javad Ghayumi, Seiyed Mohammad Ali Moarref, Ali Reza |
author_facet | Fallahi, Mohammad Javad Ghayumi, Seiyed Mohammad Ali Moarref, Ali Reza |
author_sort | Fallahi, Mohammad Javad |
collection | PubMed |
description | Background: It was hypothesized that the use of Pentoxifylline would increase arterial O2 saturation and increase exercise tolerance in patients with Chronic Obstructive Pulmonary Disease (COPD). Methods: We tested this hypothesis in 23 patients with COPD and pulmonary hypertension. Patients were randomized to receive Pentoxifylline or placebo, each for a 12-week period, in a prospective, double-blind study to assess the effects of Pentoxifylline on oxygen saturation and exercise tolerance via pulse oximetry and the 6-Minute Walk Test (6MWT). Results: At the end of the 12 weeks, the six-minute walk distance rose from 351.9±65 meters to 393±67 meters in the Pentoxifylline group (10 patients) and increased from 328±79 meters to 353±66 meters in the placebo group (10 patients) (P=0.142). Resting oxygen saturation by pulse oximetry changed from 87±4% to 85±14% in the Pentoxifylline group and from 88±3% to 88±2% in the placebo group (P=0.676). There were no significant changes in dyspnea severity index and heart rate before and after the 6MWT. Conclusion: Pentoxifylline does not seem to improve exercise capacity and dyspnea in patients with severe and very severe COPD. |
format | Online Article Text |
id | pubmed-3771218 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Shiraz University of Medical Sciences |
record_format | MEDLINE/PubMed |
spelling | pubmed-37712182013-09-12 Effects of Pentoxifylline on Oxygenation and Exercise Tolerance in Patients with Severe Chronic Obstructive Pulmonary Disease Fallahi, Mohammad Javad Ghayumi, Seiyed Mohammad Ali Moarref, Ali Reza Iran J Med Sci Original Article Background: It was hypothesized that the use of Pentoxifylline would increase arterial O2 saturation and increase exercise tolerance in patients with Chronic Obstructive Pulmonary Disease (COPD). Methods: We tested this hypothesis in 23 patients with COPD and pulmonary hypertension. Patients were randomized to receive Pentoxifylline or placebo, each for a 12-week period, in a prospective, double-blind study to assess the effects of Pentoxifylline on oxygen saturation and exercise tolerance via pulse oximetry and the 6-Minute Walk Test (6MWT). Results: At the end of the 12 weeks, the six-minute walk distance rose from 351.9±65 meters to 393±67 meters in the Pentoxifylline group (10 patients) and increased from 328±79 meters to 353±66 meters in the placebo group (10 patients) (P=0.142). Resting oxygen saturation by pulse oximetry changed from 87±4% to 85±14% in the Pentoxifylline group and from 88±3% to 88±2% in the placebo group (P=0.676). There were no significant changes in dyspnea severity index and heart rate before and after the 6MWT. Conclusion: Pentoxifylline does not seem to improve exercise capacity and dyspnea in patients with severe and very severe COPD. Shiraz University of Medical Sciences 2013-06 /pmc/articles/PMC3771218/ /pubmed/24031106 Text en © 2013: Iranian Journal of Medical Sciences This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Fallahi, Mohammad Javad Ghayumi, Seiyed Mohammad Ali Moarref, Ali Reza Effects of Pentoxifylline on Oxygenation and Exercise Tolerance in Patients with Severe Chronic Obstructive Pulmonary Disease |
title | Effects of Pentoxifylline on Oxygenation and Exercise Tolerance in Patients with Severe Chronic Obstructive Pulmonary Disease |
title_full | Effects of Pentoxifylline on Oxygenation and Exercise Tolerance in Patients with Severe Chronic Obstructive Pulmonary Disease |
title_fullStr | Effects of Pentoxifylline on Oxygenation and Exercise Tolerance in Patients with Severe Chronic Obstructive Pulmonary Disease |
title_full_unstemmed | Effects of Pentoxifylline on Oxygenation and Exercise Tolerance in Patients with Severe Chronic Obstructive Pulmonary Disease |
title_short | Effects of Pentoxifylline on Oxygenation and Exercise Tolerance in Patients with Severe Chronic Obstructive Pulmonary Disease |
title_sort | effects of pentoxifylline on oxygenation and exercise tolerance in patients with severe chronic obstructive pulmonary disease |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3771218/ https://www.ncbi.nlm.nih.gov/pubmed/24031106 |
work_keys_str_mv | AT fallahimohammadjavad effectsofpentoxifyllineonoxygenationandexercisetoleranceinpatientswithseverechronicobstructivepulmonarydisease AT ghayumiseiyedmohammadali effectsofpentoxifyllineonoxygenationandexercisetoleranceinpatientswithseverechronicobstructivepulmonarydisease AT moarrefalireza effectsofpentoxifyllineonoxygenationandexercisetoleranceinpatientswithseverechronicobstructivepulmonarydisease |